Buprenorfin

Nama sistematis (IUPAC)
	(2S)-2-[(5R,6R,7R,14S)-17-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylbutan-2-ol
Data klinis
Nama dagang	Subutex, Sublocade, others
AHFS/Drugs.com	monograph
MedlinePlus	a605002
Data lisensi	EMA:pranala, US Daily Med:pranala
Kat. kehamilan	C(AU) ?(US)
Status hukum	Dikontrol (S8) (AU) ? (CA) ? (UK) Schedule III (US)
Kemungkinan; ketergantungan	Psychological: High; Physical: Moderate
Rute	Under the tongue, through the cheek, IM, transdermal, intranasal, rectally, by mouth
Data farmakokinetik
Bioavailabilitas	Sublingual: 30%; Intranasal: 48%; Buccal: 65%
Ikatan protein	96%
Metabolisme	Liver (CYP3A4, CYP2C8)
Waktu paruh	37 hours (range 20–70 hours)
Ekskresi	Biliary and kidney
Pengenal
Kode ATC	?
Data kimia
Rumus	C29H41NO4
SMILES	eMolecules & PubChem
	InChI InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1 ; Key:RMRJXGBAOAMLHD-IHFGGWKQSA-N ;

Buprenorfin (Buprenorphine), adalah obat golongan opioid yang digunakan untuk mengatasi gangguan penggunaan opioid, nyeri akut, dan nyeri kronis . ^[7] Rute pemberian obat bisa digunakan di bawah lidah, di pipi, melalui injeksi, sebagai plester transdermal, atau sebagai implan . ^[7] ^[8]. Formulasi kombinasi buprenorfin, dan nalokson (Suboxone) direkomendasikan untuk subtitusi dari pecandu narkoba juga digunakan secara injeksi. ^[7] Sedangkan untuk terapi pereda nyeri pada obat ini digunakan secara maksimal, dan hanya dalam waktu satu jam dengan efek terapi bertahan hingga 24 jam. ^[7]

Referensi

^ Health Canada (6 December 2004). "ARCHIVED - Report Stakeholder Workshop on a National Buprenorphine Program". aem. Diarsipkan dari versi asli tanggal 26 March 2020. Diakses tanggal 10 January 2020.
^ Bonewit-West, Kathy; Hunt, Sue A.; Applegate, Edith (2012). Today's Medical Assistant: Clinical and Administrative Procedures (dalam bahasa Inggris). Elsevier Health Sciences. hlm. 571. ISBN 9781455701506. Diarsipkan dari versi asli tanggal 28 July 2020. Diakses tanggal 29 July 2020.
^ Mendelson J, Upton RA, Everhart ET, Jacob P, Jones RT (January 1997). "Bioavailability of sublingual buprenorphine". Journal of Clinical Pharmacology. 37 (1): 31–7. doi:10.1177/009127009703700106. PMID 9048270.
^ Eriksen J, Jensen NH, Kamp-Jensen M, Bjarnø H, Friis P, Brewster D (November 1989). "The systemic availability of buprenorphine administered by nasal spray". The Journal of Pharmacy and Pharmacology. 41 (11): 803–5. doi:10.1111/j.2042-7158.1989.tb06374.x. PMID 2576057.
^ "Buprenorphine / Naloxone Buccal Film (BUNAVAIL) C-III" (PDF). Pharmacy Benefits Management (PBM) Services. September 2014. Diarsipkan dari versi asli (PDF) tanggal 20 October 2020.
^ [https://web.archive.org/web/20201030071038/https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205637s000lbl.pdf Diarsipkan 30 October 2020 di Wayback Machine. BUNAVAIL (buprenorphine and naloxone) buccal film, CIII [prescribing information online]]. BioDelivery BioDelivery Sciences International, Inc. (BDSI), Raleigh, NC. Jun 2014.
^ ^a ^b ^c ^d "Buprenorphine Hydrochloride". drugs.com. American Society of Health-System Pharmacists. 26 January 2017. Diarsipkan dari versi asli tanggal 18 July 2017. Diakses tanggal 17 March 2017. Kesalahan pengutipan: Tanda <ref> tidak sah; nama "ASHP2017" didefinisikan berulang dengan isi berbeda
^ "Press Announcements – FDA approves first buprenorphine implant for treatment of opioid dependence". FDA (dalam bahasa Inggris). Diarsipkan dari versi asli tanggal 30 November 2017. Diakses tanggal 12 December 2017.

[1] Health Canada (6 December 2004). "ARCHIVED - Report Stakeholder Workshop on a National Buprenorphine Program". aem. Diarsipkan dari versi asli tanggal 26 March 2020. Diakses tanggal 10 January 2020.

[2] Bonewit-West, Kathy; Hunt, Sue A.; Applegate, Edith (2012). Today's Medical Assistant: Clinical and Administrative Procedures (dalam bahasa Inggris). Elsevier Health Sciences. hlm. 571. ISBN 9781455701506. Diarsipkan dari versi asli tanggal 28 July 2020. Diakses tanggal 29 July 2020.

[pmid9048270-3] Mendelson J, Upton RA, Everhart ET, Jacob P, Jones RT (January 1997). "Bioavailability of sublingual buprenorphine". Journal of Clinical Pharmacology. 37 (1): 31–7. doi:10.1177/009127009703700106. PMID 9048270.

[pmid2576057-4] Eriksen J, Jensen NH, Kamp-Jensen M, Bjarnø H, Friis P, Brewster D (November 1989). "The systemic availability of buprenorphine administered by nasal spray". The Journal of Pharmacy and Pharmacology. 41 (11): 803–5. doi:10.1111/j.2042-7158.1989.tb06374.x. PMID 2576057.

[5] "Buprenorphine / Naloxone Buccal Film (BUNAVAIL) C-III" (PDF). Pharmacy Benefits Management (PBM) Services. September 2014. Diarsipkan dari versi asli (PDF) tanggal 20 October 2020.

[:2-6] [https://web.archive.org/web/20201030071038/https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205637s000lbl.pdf Diarsipkan 30 October 2020 di Wayback Machine. BUNAVAIL (buprenorphine and naloxone) buccal film, CIII [prescribing information online]]. BioDelivery BioDelivery Sciences International, Inc. (BDSI), Raleigh, NC. Jun 2014.

[ASHP2017-7] "Buprenorphine Hydrochloride". drugs.com. American Society of Health-System Pharmacists. 26 January 2017. Diarsipkan dari versi asli tanggal 18 July 2017. Diakses tanggal 17 March 2017. Kesalahan pengutipan: Tanda <ref> tidak sah; nama "ASHP2017" didefinisikan berulang dengan isi berbeda

[8] "Press Announcements – FDA approves first buprenorphine implant for treatment of opioid dependence". FDA (dalam bahasa Inggris). Diarsipkan dari versi asli tanggal 30 November 2017. Diakses tanggal 12 December 2017.

[7]

[8]

[2]

[3]

[4]

[5]

[6]